This month's top research papers
Our pick of new research on safer supply, drug checking, treatment, STBBI and the structural conditions shaping substance use health. 🍁 marks Canadian research.
Safer supply
1. 🍁 Lasocka A, Kerr T, Choi J, et al. Safer supply program enrollment motivations and medication preferences among people who use drugs in Vancouver, Canada. International Journal of Drug Policy. 2026 (online ahead of print, Oct 15). PMID: 42879841. Link
Puts client voices at the centre: people in Vancouver explain why they enrolled in safer supply and which medications they prefer, timely as prescribing declines across BC.
Harm reduction and overdose prevention
2. Studnicki O, Shang M, Hull I, Schultz K, Halpern D, Bell A, Liebschutz JM, Jawa R. "You do what you have to do": risk environments in xylazine wound care. Substance Use & Addiction Journal. 2026. Link
Looks at how the settings people live and use in shape their ability to care for xylazine-related wounds.
3. Schneider KE, Youstra CA, Nestadt DF, Martin EM, Rouhani S, St. John AT, et al. Solitary drug use: frequency, motivations, and overdose prevention strategies employed by people who use drugs. Substance Use & Misuse. 2026. doi:10.1080/10826084.2026.2747708. Link
Examines how often and why people use alone, and the strategies they use to stay safe, the scenario where most overdose deaths occur.
4. 🍁 Proceviat C, Lei J, Morgan J, Dickhout P, Young S, Ti L, Nolan S. Awareness, interest and use of a hospital-based overdose prevention site in Vancouver, Canada: a cross-sectional study. Harm Reduction Journal. 2026 (published online Sep 29). doi:10.1186/s12954-026-01535-6. Link
Among 142 hospital patients who inject drugs at St. Paul's, 84% knew about the in-hospital overdose prevention site and 58% had used it. Use was highest among those with past overdoses or patient-initiated discharges, the people hospitals most need to keep safe and in care.
Clinical care
5. Bal M, Mendis N, Bennett M, Kinniburgh D, Weleff J. Probable cychlorphine exposure in a patient with opioid use disorder: a case report. American Journal on Addictions. 2026. doi:10.1111/ajad.70218. Link
A case report of probable cychlorphine exposure in a person with opioid use disorder, an early clinical signal of a newer substance in the unregulated supply.
6. Wilkerson RG, Tran Q. Medetomidine in the illicit drug supply: emergency management of intoxication and withdrawal. The Journal of Emergency Medicine. 2026 (available online Nov 3). Link
An open-access clinical review on recognizing and managing medetomidine intoxication and withdrawal, a newer sedative adulterant now turning up in the unregulated supply.
Treatment and care models
7. 🍁 Colizza K, Grover M, Crockford D, Knight E, Leary T, Martell D. Canadian Society of Addiction Medicine position statement on opioid use disorder treatment in corrections. Canadian Journal of Addiction. 2026. doi:10.1097/CXA.0000000000000291. Link
Canada's addiction medicine society sets out its position on treating opioid use disorder in jails and prisons, timely as post-release overdose risk stays high.
8. 🍁 Marchand K, Turuba R, Cameron V, Eekhoudt CR, Fast D, Knight R, Marsh DC, Ignaszewski MJ, Sassi R, Mathias S, Barbic S. Optimizing the quality of opioid agonist treatment for youth: experts' recommendations for youth-centred models of care. Addiction Science & Clinical Practice. 2026 (published online Oct 23). doi:10.1186/s13722-026-00729-4. Link
Seventeen BC youth, caregivers, providers and decision-makers set out eight recommendations for youth OAT, including trusting relationships, all medication options on the table, shared induction and tapering plans, low-barrier settings and caregiver support.
9. 🍁 Abramowich A, Dickhout P, Nolan S, Eekhoudt CR, Roberge S, De Wolfe T, Mundel E, Janssen RM, Ryan A, Johnson C, Lemchuk-Favel L, Johnson H, Bowles JM, Dennis BB. Implementing a new model of substance use care in British Columbia: healthcare staff experiences from the Road to Recovery initiative. Addiction Science & Clinical Practice. 2026. PMID: 42983564. Link
Staff describe putting BC's Road to Recovery model of substance use care into practice, a close look at implementation as provinces shift toward recovery-oriented systems.
Peer work
10. Pasman E, Drazdowski TK, Mabila P, Patterson D, McCabe SE, Resko SM, Sheidow AJ. Expert recommendations for training peer workers to provide non-abstinent recovery support: a real-time Delphi study. Journal of Substance Use and Addiction Treatment. 2026. Link
Builds expert consensus on how to train peer workers to support recovery that does not require abstinence.
STBBI and substance use health
11. 🍁 Mackrell L, Carter M, Antoun JP, Guan H, Oglaza P, Stoner B, O'Byrne P, Southall M, Baldeh T, Larkin N, Burbidge J, Belanger K, Keck A, Martinez-Cajas J, Rasinaho B, St John M, Tran V, Saeed S. Females at the intersection: housing instability, drug use, and syphilis risk among street-involved populations in Ontario, Canada. International Journal of Drug Policy. 2026;157(Pt A):105482. doi:10.1016/j.drugpo.2026.105482. Link
Among 1,281 street-involved people in the SPRITE outreach study, new syphilis infections were higher in females (4.6% vs 3.2%), and drug use plus unstable housing compounded their risk. The authors call it a syndemic that may help explain rising syphilis among women.
12. Hoffman K, Leichtling G, Shin S, Seaman A, Gailey T, Spencer HC, Korthuis PT. "I really can't imagine anything that could've been more easy": patient perspectives on low-threshold peer-facilitated telemedicine hepatitis C treatment for people who use drugs. Addiction Science & Clinical Practice. 2026;21:79. doi:10.1186/s13722-026-00704-z. Link
Interviews with 34 people in rural Oregon show why peer-supported, same-day telemedicine HCV care worked: nonjudgmental staff, care brought to where people are, and practical help with transport, meds and basic needs.
13. Walters SM, Do H, Jaiswal J, Khezri M, Ivasiy R, Friedman SR, Ompad DC, El-Shahawy O, Lim S, Schneider JA, Bouris A, Bluthenthal RN, Earnshaw VA, Huh J. HIV-stigmatizing beliefs and attitudes as a barrier to early PrEP care continuum engagement among people who inject drugs. AIDS and Behavior. 2026 (online ahead of print, Apr 9). doi:10.1007/s10461-026-05112-7. Link
Among 262 HIV-negative people who inject drugs in Los Angeles and Denver, HIV stigma was tied to lower PrEP awareness and knowledge. Once informed, 56% were willing to take daily oral PrEP, pointing to peer-led education and stigma reduction.
14. 🍁 Sahakyan Y, et al. Impact of the COVID-19 pandemic and public health measures on hepatitis C treatment initiation in Ontario, Canada. Viruses. 2026. doi:10.3390/v18101090. Link
In 63,691 treatment-eligible Ontarians, HCV treatment starts dipped in 2020–2022, though the pandemic's effect was not statistically significant and depended on the comparison period.
Drug checking
15. 🍁 Canada's Drug Agency. Drug-checking technologies to detect compositions of unregulated substance samples. Canadian Journal of Health Technologies. 2026. Link
Test strips are highly sensitive for their target drug, spectroscopy shows more of what is in a sample, and combining methods cuts false negatives. No cost-effectiveness studies met inclusion.
16. Fernando H, Whitehead H, Black NJ, West ED, Znamierowski E, Edelmann A, Green TC, Lieberman M. Drug trash to treasure: quantitative mass spectrometric analysis of residual drugs from used lateral flow immunoassay test strips and syringe plungers. Harm Reduction Journal. 2026 (published online Oct 20). doi:10.1186/s12954-026-01537-4. Link
Residue on used test strips and syringe plungers can be lab-tested: all 21 drugs studied, including carfentanil and medetomidine, were still recoverable after four weeks at room temperature. A safer, simpler way to feed drug supply monitoring without collecting drug samples.
Public opinion, media and policy
17. 🍁 Goodyear T, Mneina M, Schlissel J, Long V, Shaffer B, Russolillo A, Jenkins E, Slemon A, Gagnon M, Greer A. Canadian news media reporting on involuntary substance use treatment and its evidence, 2020–2025: "At the cutting edge of debate, science and policy". International Journal of Drug Policy. 2026;157(Pt A):105486. doi:10.1016/j.drugpo.2026.105486. Link
Evidence for involuntary treatment is limited and mixed, yet news coverage frames pilots as a way to produce that evidence, helping build public support for an ethically contested intervention.
18. 🍁 Zanette M, Enns B, Carter A, Compton M, Daly P, Davison C, Gustafson R, Hedden L, Kerr T, Schnepel K, Nosyk B. A review of policy actions implemented during a toxic drug public health emergency in British Columbia, Canada (2016–2024). International Journal of Drug Policy. 2026;157(Pt A):105509. Link
Takes stock of nearly a decade of BC's policy response to the toxic drug emergency, as public opinion on that response has grown more skeptical.
19. 🍁 DeVera P. A critical discourse analysis of supervised consumption site advocacy in mainstream media. PhD thesis. University of Waterloo (UWSpace). 2026. Link
Analyzes how supervised consumption site advocacy is framed in mainstream news, useful context as sites close in Alberta and Ontario.
20. 🍁 Kerr T, Bogosavljević K, Hyshka E, Karamouzian M, Hamzat B, Kolla GA, Ledlie S, Nosyk B, Werb D, Bayoumi A, Gomes T. Reconsidering the Alberta study of the closure of the Red Deer supervised consumption site. International Journal of Drug Policy. 2026. Link
Revisits the Alberta government-funded study of Red Deer's site closure, which was published in Addiction and cited by Alberta and Ontario as grounds to close more sites. Essential reading for anyone responding to closure decisions.